Mid-Day Market Update: Crude Oil Down Over 1%; Intellia Therapeutics Shares Jump
Midway through trading Monday, the Dow traded down 0.52% to 34,253.86 while the NASDAQ rose 0.72% to 14,463.56. The S&P also fell, dropping 0.01% to 4,280.50.
44 Stocks Moving In Monday’s Mid-Day Session
Gainers
Intellia Therapeutics, Inc. (NASDAQ: NTLA) shares climbed 43.5% to $127.44 after the company announced positive clinical data for its CRISPR therapy.
Needham Maintains Buy on Exelixis, Lowers Price Target to $30
Needham analyst Chad Messer maintains Exelixis (NASDAQ:EXEL) with a Buy and lowers the price target from $33 to $30.
Exelixis Shares Drop On Mixed Results For Cabometyx Combo In Early Liver Cancer
Exelixis Inc (NASDAQ:EXEL) and Ipsen (OTC:IPSEY) have announced mixed interim results from the COSMIC-312 Phase 3 trial evaluating cabozantinib (Cabometyx) in combination with Roche…
The Week Ahead In Biotech: Mediwound, Provention FDA Decisions, IPOs, Pending Clinical Readouts In Focus
Biotech stocks reversed course and closed the week ended June 25 higher, thanks to the positive broader market sentiment.
Exelixis 8-K Shows. Co. Received Notice Letters From Teva Related To Abbreviated New Drug Application For CABOMETYX Tablets; Co. Filed Complaint In US For Patent Infringement Against Teva
In May 2021, Exelixis, Inc. (“Exelixis”) received notice letters from Teva Pharmaceuticals USA, Inc. and Teva Pharmaceuticals Development, Inc. (collectively, “Teva”) regarding an Abbreviated New